Canadian Adult Obesity Clinical Practice Guidelines 1 KEY MESSAGES FOR HEALTHCARE PROVIDERS • Bariatric surgery should be considered for patients with severe obesity (body mass index (BMI) ≥ 35 kg/m 2 ) and obesity-related diseases, or BMI ≥ 40 kg/m 2 without obesity-related diseases. • Bariatric surgery could be considered for patients with obesity (BMI ≥ 30 kg/m 2 ) with severe obesity-related diseases not responding to medical management. • The choice of bariatric procedure should be tailored to pa- tients’ needs, in collaboration with a multidisciplinary team and based on the discussion of risks, benefits and side-effects. • Several procedures are currently performed in Canada (ad- justable gastric banding, sleeve gastrectomy, gastric bypass, duodenal switch and others) but variations exist. • For patients with severe obesity, surgery offers superior out- comes compared to best medical management, in terms of quality of life, long-term weight loss and resolution of obesity-related diseases, especially type 2 diabetes, sleep apnea, fatty liver disease and hypertension. • Laparoscopic approach should be standard and is associated, for most patients, with a low mortality rate (< 0.1%) and low serious complication rate (< 5%). • Bariatric surgery improves life expectancy. • Novel surgical and endoscopic approaches are being used and developed and can represent an option for specific patients. Bariatric Surgery: Surgical Options and Outcomes Laurent Biertho MD i , Dennis Hong MD MSc ii , and Michel Gagner MD iii i) Department of Surgery, Laval University ii) Division of General Surgery, McMaster University iii) Herbert Wertheim School of Medicine, Florida International University; Hôpital du Sacre Coeur de Montreal Cite this Chapter Biertho L, Hong D, Gagner M. Canadian Adult Obesity Clinical Practice Guidelines: Bariatric Surgery: Surgical Options and Outcomes. Available from: https://obesitycanada.ca/guidelines/surgeryoptions. Accessed [date]. Update History Version 1, August 4, 2020. Adult Obesity Clinical Practice Guidelines are a living document, with only the latest chapters posted at obesitycanada.ca/guidelines. RECOMMENDATIONS 1. Bariatric surgery can be considered for people with BMI ≥ 40 kg/m 2 or BMI ≥ 35 kg/m 2 with at least one adiposity-related disease to (Level 4, Grade D, Consensus) to: a. Reduce long-term overall mortality (Level 2b, Grade B); 1,2 b. Induce significantly better long-term weight loss com- pared to medical management alone (Level 1a, Grade A); 3 c. Induce control and remission of type 2 diabetes, in com- bination with best medical management, over best med- ical management alone (Level 2a, Grade B); 4,5 d. Significantly improve quality of life (Level 3, Grade C); 6 e. Induce long-term remission of most obesity-related diseases, including dyslipidemia (Level 3, Grade C), 7 hypertension (Level 3, Grade C), 8 liver steatosis and nonalcoholic ste- atohepatitis (Level 3, Grade C). 9
13
Embed
Bariatric Surgery: Surgical Options and Outcomesobesitycanada.ca/wp-content/uploads/2020/08/12-Bariatric-Surgery... · Many studies have confirmedthe long-term superior weight loss
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Canadian Adult Obesity Clinical Practice Guidelines 1
a. Reducelong-termoverallmortality(Level2b,GradeB);1,2
b. Induce significantly better long-term weight loss com-paredtomedicalmanagementalone(Level1a,GradeA);3
c. Inducecontrolandremissionoftype2diabetes,incom-binationwithbestmedicalmanagement,overbestmed-icalmanagementalone(Level2a,GradeB);4,5
d. Significantlyimprovequalityoflife(Level3,GradeC);6
e. Inducelong-termremissionofmostobesity-relateddiseases,includingdyslipidemia(Level3,GradeC),7hypertension(Level3,GradeC),8liversteatosisandnonalcoholicste-atohepatitis(Level3,GradeC).9
Canadian Adult Obesity Clinical Practice Guidelines 2
Introduction
Formost individualswithsevereobesity,healthbehaviour inter-ventions, perhaps effective in inducing short-lived weight loss,arefrequentlyineffectiveforlong-termweightlossmaintenanceand durablemetabolic recovery. For example, the vastmajority(74%)individualslivingwithsevereobesityundergoingintensivebehavioural intervention in the LookAHEAD (Action forHealthinDiabetes)trialdidnotmaintainaweightlossgreaterorequalto10%ofinitialbodyweightafterfouryears.14Accordingly,fewbenefitswereobservedinthisstudysubgroupfromthecardiovascu-larriskstandpoint.14Bariatricsurgeries,alsocalledmetabolicsurger-ies,nowclearlyrepresentareasonableoptionfortheseindividuals,especiallysincetheseminaldemonstrationsthatbariatricsurgeryismoreeffectivethanstandardmedicalapproaches,includinguseofmedicationanddietarycounselling,toimproveglycemiccontrol insevereobesityanduncontrolledtype2diabetesmellitus(T2DM).4,5
Which patients should be offered bariatric surgery?
Thefirst-linemanagementofobesity should includeamultidis-ciplinaryevaluationwithnutritionalandmedical counselling,as
Anumberofsurgicalprocedureshaveemergedoverthelast40years,includingRoux-en-Ygastricbypassin1971,adjustablegas-tricbandingin1980,duodenalswitchin1989andsleevegastrec-tomy in2000.16 Indications for the surgicalmanagementof se-vereobesitywereoutlinedbytheNationalInstituteofHealth(NIH)consensusdevelopmentpanelin1991andcontinuetorepresentgenerallyacceptedguidelines.17 Interestingly,eventhoughtheseguidelinesweredevelopedalmost30yearsago,andwerebasedonexpertopinions,theyhavenotyetbeenrevised.Potentialcan-didatesshouldbeagedbetween18and60yearsandwillingtoparticipateintheirtreatmentandlong-termfollow-up.
Patientswith a BMI between35 and40 kg/m²with at least onemajor obesity-related disease (e.g., T2DM, obesity-related cardiacdisease, sleepapnea),orpatientswithaBMI≥40kg/m²withorwithout associated diseases, are potential surgical candidates. Inaddition,bariatric surgerymaybeoffered topatientswithobesity
KEY MESSAGES FOR PEOPLE LIVING WITH SEVERE OBESITY
• Ifyouaresufferingfromsevereobesity,youshouldenquireaboutbariatricsurgery.Inyoursituation,behaviouralinter-ventionsandmedicaltherapiesareimportantbutusuallynoteffective enough to obtain significant long-term weightlossandremissionofobesity-relateddiseases.
• Bariatric surgery in combination with modifications tohealthbehaviourscanresultinsignificantlong-termweightloss(20%to40%ofyourbodyweight)andcontrol,or,insomecases,completeremission,ofobesity-relateddiseases,includingtype2diabetes,sleepapnea,fattyliverdiseaseandhypertension.
• Different surgical options exist (e.g., sleeve gastrectomy,gastricbypassandduodenalswitch),withdifferent levelsofeffectiveness.Youshouldhaveanextensivediscussionwiththesurgicalteambeforedecidingwhichsurgicaloptionseemstobethebestforyou.
• Allsurgerieshavesomeadverseeffectsandpotentialrisks,and require lifelong management to follow-up, mineralandvitaminsupplementations,andbehaviouralchanges.
2.Bariatric surgery should be considered in patients withpoorlycontrolledtype2diabetesandClassIobesity(BMIbetween30and35kg/m2) (Level1a;GradeA)10despiteoptimalmedicalmanagement.
3.Bariatric surgerymaybe considered forweight loss and/or to control adiposity-related diseases in persons withClass1obesity,inwhomoptimalmedicalandbehaviouralmanagementhavebeeninsufficienttoproducesignificantweightloss(Level2a,GradeB).11
4.Wesuggestthechoiceofbariatricprocedure(sleevegas-trectomy, gastric bypass or duodenal switch) be decided
Canadian Adult Obesity Clinical Practice Guidelines 3
(BMI ≥ 30 kg/m²) and significant obesity-associated disease(s),when psychological and behavioural interventions and medicalmanagementareinsufficienttoachieveoptimalweightlossandcontrolofcomorbidities.11Thesepatientsshouldbeevaluatedandcarefullyselectedbyamultidisciplinaryteamexperienced inthefieldofobesitysurgery.Teammembersshouldeducatepatientsregardingtherisks,benefitsandalternativestobariatricsurgery,includinguseofantiobesitymedications.Patientsshouldalsoun-derstandtheneedforlifelongmedicalsurveillancetopreventandcorrectpotential long-termnutritionaldeficienciesaftersurgery.Contraindications for bariatric surgery include recent substanceabuse (alcohol, drugs), non-stable psychiatric conditions (i.e.,changesinpsychiatricmedicationsinthelastsixmonths),adiag-nosisofcanceroranexpectedlifeexpectancylessthanfiveyears.
Even though an age limit of 60 years is considered in theNIHrecommendations,multiple studies have assessed the risks andbenefitsofbariatricsurgeryintheelderly.Thesearesummarizedin a systematic review that identified 26 articles encompassing8,149patients.18Pooled30-daymortalitywas0.01%andover-all complication ratewas 14.7%.At one-year follow-up,meanexcessweight losswas53.8%,diabetes resolutionwas54.5%,hypertensionresolutionwas42.5%andlipiddisorderresolutionwas41.2%.Theauthorsconcludethatoutcomesandcomplica-tionratesofbariatricsurgeryinpatientsolderthan60yearsarecomparabletothoseinayoungerpopulation,independentofthetypeofprocedureperformed.Patientsshouldnotbedeniedbar-iatricsurgerybecauseoftheiragealone.
SurgicalproceduresaredescribedinFigure1.Historically,weight-losssurgerieswereclassifiedbasedontheirsupposedmechanismsofaction.Adjustablegastricbandingwasconsideredasapurelyrestrictivesurgery,butahighlong-termcomplicationrateassoci-atedwithweightregain,slippageanderosionshasledtoalossofinterestwiththisprocedureinfavourofsurgerieswithametabolicimpact.Hypoabsorptivesurgerieswere thought todecrease theabsorptionofnutrientsbybypassingportionsofthesmallintestine(i.e.,gastricbypassorduodenalswitch).However,mechanisticstud-ieshavedescribedmanymetabolicmodifications,includingchangesinincretins,guthormones,bileacidslevelsandmicrobiota,whichhasledtoreferringtothesesurgeriesas“metabolicoperations.”
Thedecisionforthetypeofsurgeryismadeincollaborationwithamultidisciplinaryteam,basedonthepatient’smedicalcondition,including weight, obesity-related diseases, expected adherencewith supplementation and follow-up, patients’ personal goalsandpreferences in termsofexpectedweight loss, resolutionofcomorbidities and side-effects. This team typicallymay include a
bariatric nurse, dietitian,mental health specialist, social workerandaninternist/bariatricphysician,inadditiontothebariatricsur-geon. Thegoal is tofindabalancebetween the complicationsand risk of mortality associated with the obesity itself, and toimprovethepatient’squalityoflife(QOL)andreduceobesity-re-lateddiseaseswhileaimingforacceptableshort-andlong-termcomplicationsandside-effectsrelatedtothesurgery itself.Asaruleofthumb,earlyandlong-termrisksandside-effects,butalsomaintenanceofweight lossand remissionofcomorbidities,areproportional to the intestinalbypass.Otherbariatricproceduressuchassingle-anastomosisduodeno-ileostomyandsingle-anasto-mosisgastricbypassarebecomingmorepopular,butarestilllack-ingsubstantialscientificrationale.Theyarediscussedinthe“Newsurgicalandendoscopicapproaches”sectionofthischapter.
Adjustable gastric banding isoneoftheproceduresthathasevolved themostover the last20years, fromanon-adjustablegastric band performed by laparotomy to laparoscopically per-formed adjustable gastric banding. Iterations of the techniquehave always aimed to reduce the complications that appearedovertime.Theprocedureconsistsinplacinganadjustablesiliconebandatthe levelofthecardia,creatingasmallstomachpouchabovetheband,withtherestofthestomachbelowtheband.Thegastricband is connectedbya silicone tube toa subcutaneousreservoir.Thereservoircanbeinflatedordeflatedtocontroltheopeningbetweenthepouchandtheremainderofthestomach.Eventhoughthisprocedure isassociatedwiththe lowestshort-term complication rate, it is associated with a high long-termcomplicationrateandweightregain,whichhasledtoitsprogres-sivereplacementbysleevegastrectomy.
Sleeve gastrectomywasfirstusedby laparoscopyasastagedapproachinordertoreduceperioperativecomplications inhighriskpatients.20Interestingly,somepatientsexperiencedapprecia-bleweightlosswithsleevegastrectomyaloneanddidnotrequiresecond-stagesurgery,thusavoidingtheside-effectsofmalabsorp-tion.Itsrelativetechnicalsimplicityandgoodoutcomesledtoaworldwidesurgeinpopularityasastand-aloneprocedure,start-ingaround2008.Thisprocedureinvolvesresectionofthelateralpart of the stomach to create a narrowgastric tube along thelesser curvature. Itpromotesweight loss through reducedmealvolumeand reducedappetite. It hasbecome themost frequentlyperformed surgical approach, representing 45.9% and 58.3%ofallsurgeriesintheworldandinNorthAmericarespectively.21 Thesenumbersarelikelytobemaintainedgiventherecentcon-firmationof thefive-year efficacyof sleevegastrectomy in tworandomizedcontrolledtrials.22,23Inaddition,sleevegastrectomyistypicallyeasiertoreviseincaseofweightregaincomparedwithRoux-en-Ygastricbypass.
Roux-en-Y gastric bypass involvesthecreationofasmallgas-tricpouchatthelevelofthecardia.Thispouchisconnectedtotheproximal smallbowelbybypassing thefirst75cm–150cmand bringing a 100 cm–150 cm alimentary limb onto the gas-tricpouch.Short-termmetabolicandhormonaleffectshavebeenstudiedextensivelyinnumerousstudies.24Ithasbeenconsideredas the gold standard in bariatric surgery until recently,when it
Canadian Adult Obesity Clinical Practice Guidelines 4
Duodenal switch combines moderate restrictive and hypoab-sorptive mechanisms by creating a wider sleeve gastrectomy,whiletheduodenumistransecteddistaltothepylorusandanas-tomosedtoa250cmalimentarylimb,leavinga100-cmcommonchannel for nutrient absorption.Duodenal switch reducesmor-bidityandmortality,improvesT2DMandcorrectsmanyfeaturesofthemetabolicsyndromeinlong-termstudies.25Thisoperationcompares very advantageously with the other surgical optionsavailable,offeringthemostpronouncedanddurableweightlossand 80%–90% remission rates for T2DM.26 Yet, the technicalcomplexityandtheriskforlong-termnutritionaldeficiencieshashindereditswidespreaduse.Accordingtothemostrecentdata,duodenalswitchrepresented1.1%ofthetotalnumberofsurger-iesworldwideand5%–6%ofallbariatricoperationsinCanada.21
ratewas higher andweight losswas less substantial thangas-tricbypass.InalargeanalysisofUnitedStatesbariatricregistries(n=134,142), sleeve gastrectomy was associated with half therisk-adjustedoddsofdeath(0.1%versus0.2%),seriousmorbidity(5.8%versus11.7%)andleak(0.8%versus1.6%)inthefirst30dayscomparedtoRoux-en-Ygastricbypass.Sleevegastrectomyappearedtobemoreeffectiveinweightlossthanadjustablegas-tricbandingandcomparablewithgastricbypass.Table1summa-rizestherisksandbenefitsofthefourdifferentsurgeries.
Metabolic effects of bariatric surgery
What Is the quality of life after bariatric surgery?
PatientslivingwithsevereobesityhavelowerperceivedhealthacrossalldimensionsofQOL.28Moreover,theimpactonfunctioningissoimportantthatsevereobesitycanbedescribedasacauseofdisability.Formostpatients,bariatricsurgeryhasasignificantpositiveinfluenceonQOL.Theimpactvariesconsiderablyacrossstudies,withbariatricsurgeryshowingasignificantlygreaterpositiveinfluenceonphysicalQOLcomparedwithmentalQOL.Also,improvementinhealth-relat-edqualityoflife(HRQOL)istypicallyassociatedwiththeamountofweightloss.Meta-analysesofshort-term(oneyear)andlong-term(≥5years)HRQOLfollowingbariatricsurgeryversusnonsurgicalmanagement inpatientswithClass IIor IIIobesity, showedevi-dence for a substantial and significant improvement inphysicalandmentalhealth favouring the surgicalgroupcomparedwithcontrols,spanningfiveto25yearsaftersurgery.29,30Inasystematicreviewcomparingbariatricsurgerytomedicaltreatmentinadultswithobesity(BMI>30kg/m2),31bariatricsurgeryresultedingreat-erimprovementsinQOLthanotherobesitytreatments.However,significantdifferencesinQOLimprovementswerefoundbetweendifferenttypesofbariatricsurgery,andgreaterimprovementsinphysicalQOLthanmentalQOLwerefound.Similarly,Lindekilke
SleevegastrectomywasalsocomparedtoRoux-en-Ygastricby-passintworandomizedcontroltrialswithfive-yearoutcomes.22,23 Roux-en-Ygastricbypassandsleevegastrectomyresultedinequiv-alent,long-standingQOLimprovement.Roux-en-Ygastricbypassresulted in more stable weight loss (75% versus 65% excessweightlossatfiveyears,p=0.017)butwasassociatedwithhigherreadmissionrates.SimilarimprovementsinQOLwerefoundinthesecondrandomizedcontroltrial;excessweightlosswas49%inthesleevegastrectomygroupversus57%intheRoux-en-Ygas-tricbypassgroup,but thedifferencedidnot reachsignificance.Overallmorbiditywas19%forsleevegastrectomyand26%forRoux-en-Ygastricbypass(p=0.19).
What are the effects on type 2 diabetes?
OverthelasttwodecadeswehavewitnessedadramaticincreaseintheincidenceofT2DM,nowaffecting10%oftheadultpopu-lation.Most(80%)isduetoexcessweightorobesityandT2DMhasbecome the leadingcauseofchronickidneydisease,blind-ness, and non-traumatic amputation. Overall, bariatric surgeryprocedureshavebeenconsistentlymoreeffectivethanstandardmedical approaches, including intensivemedical treatment andpsychological/behaviouralinterventionstoinducedurablecontrolandremissionofT2DM.35
TheSOSstudyisaprospectivecontrolledtrialwithoneofthelon-gestperiodsoffollow-upinthebariatricliterature.Thisstudyhasshown impressive resultswith respect to sustained remissionofT2DM.35Attwo(n=1762)and10years(n=1216),remissionrateswere72%and36%,respectively, inthepooledsurgicalgroup.Reductionsinglucose,insulinandhomeostaticmodelassessmentfor insulin resistance increasedwith increasingweight loss,andchanges were typically related to weight change within eachsurgerygroup.Several randomizedcontrol trialshavespecifical-lystudiedT2DMresponsetodifferentsurgicalproceduresversusmedicaltreatment.Mingroneetal.4reportedratesofremissionofdiabetesatthreeyearstobe75%and95%inRoux-en-Ygastricbypassandduodenalswitchgroups,comparedtonoresponsewithmedicalinterventionalone.Atfiveyears,remissionwasmaintainedin37%of theRoux-en-Ygastricbypasspatientsand63%of thebiliopancreatic diversionpatients.4 Further, Schauer et al.5 stud-ied the impactofRoux-en-Ygastricbypass, sleevegastrectomyandbestmedicalmanagementforpatientswithpoorlycontrolledT2DMandsevereobesity (BMI27to43kg/m2).At threeyears,Roux-en-Ygastricbypass (n=50)andsleevegastrectomy (n=50)resulted in improved diabetes outcomes and remission in 42%and 37%of patients, respectively, compared to 12% achievedwithmedicaltherapy(n=50).Atfiveyears,5thecriterionfortheprimaryendpointwasmetby5%ofpatientswhoreceivedmed-icaltherapyalone,comparedto29%whounderwentRoux-en-Ygastricbypassand23%whounderwentsleevegastrectomy.Meanreductioninglycatedhemoglobinwas2.1%vs.0.3%(p=0.003)in
Canadian Adult Obesity Clinical Practice Guidelines 6
thesurgeryversusmedicalcroup.ChangesfrombaselineobservedintheRoux-en-Ygastricbypassandsleevegastrectomygroupswerealsosuperiortothechangesseeninthemedicaltherapygroupwithrespect to body weight. These changes were −23%, −19% and−5%intheRoux-en-Ygastricbypass,sleevegastrectomyandmed-icaltherapygroups,respectively;thetriglyceridelevelswere−40%,−29% and −8%; high density lipoprotein cholesterol levels were32%,30%and7%;useofinsulinwas−35%,−34%and−13%;andQOLmeasureswerep<0.05forallcomparisons.Five-to20-yearremissionratesafterduodenalswitchareevenhigher,withobserva-tionalstudiesshowingcompleteremissionintherangeof93%anddiscontinuationofinsulintherapyin97%.25
In general,metabolic outcomes of adjustable gastric banding arelessimpressivecomparedwithbypassprocedures.Inarandomizedcontroltrialcomparingadjustablegastricbandingtointensivemed-icaldiabetesandobesitymanagement inpatientswithT2DMandBMIof30–45kg/m2,36laparoscopicadjustablegastricbandingandmedicalprogramshadsimilarone-yearbenefitsondiabetescontrol,cardiometabolicriskandpatientsatisfaction.Theproportionmeetingtheprimaryglycemicendpointwasachievedin33%ofthelaparo-scopicadjustablegastricbandingpatientsand23%oftheintensivemedicaldiabetesandweightmanagementpatients(p=.457).Gly-catedhemoglobin(HbA1c)reductionwassimilarbetweengroupsatboththreeand12months(-1.2+/-0.3vs-1.0+/-0.3%;p=.496).Weightlosswassimilaratthreemonthsbutgreaterat12monthsafter laparoscopicadjustablegastricbanding.TheseoutcomesandothersfavourmetabolicsurgeriesincasesofT2DM.
An abundant literature, including prospective and randomizedtrialscomparingdifferentmetabolicprocedurestomedicaltreat-ment, have been identified by our literature search. All studiesconsistently showed superior control and remissionofT2DM inthe surgical arms37–39, including superiorweight loss and lowerHbA1cthreeyearsafterduodenalswitchcomparedwithRoux-en-Ygastricbypass.40Variationsinreportedoutcomesaremultifacto-rial and include differences in study design, surgical technique,durationoffollow-upandpatientcharacteristics,suchashigherpre-surgical BMI and shorter durationof T2DM (bothofwhichconferhigherlikelihoodofremission).41
Also, continuedmonitoringofglycemic control iswarrantedbe-cause theeffectof surgery tends todiminishover timewithpo-tentialrelapseofhyperglycemia.38TheplaceofmetabolicsurgeryinthemanagementofT2DMwasultimatelyrecognizedbytheIn-ternationalFederationonDiabetesin201142andtheCanadianDi-abetesAssociationin2013.43BothstatedthatsurgeryrepresentsavalidoptionforT2DMmanagementinpatientswithsevereobesitywhohavefailedinitialmedicalandnutritionalmanagement.
ed improvement of hypertension in 32,628 of 51,241 patients(OR=13.24;95%CI7.7,22.7;p<0.00001);46studiesreport-ed the resolutionofhypertension in24,902of49,844patients(OR=1.7; 95%CI 1.1, 2.6; p=0.01).Another systematic reviewand meta-analysis on the early impact of bariatric surgery onT2DM,hypertensionandhyperlipidemiawasperformedbyRiccietal.44Therewasanoverallreductionofcardiovascularriskafterbariatricsurgery.Accordingtotheiranalysis,aBMIreductionoffive after surgery corresponds to a T2DM reduction of 33%, ahypertension reductionof27%andahyperlipidemia reductionof20%.Theimpactofsleevegastrectomyonhypertensionwasassessedinasystematicreview.45Atotalof33studieswereiden-tified,involvingatotalof3997patients.Laparoscopicsleevegas-trectomyresultedinresolutionofhypertensionin58%ofpatientsandimprovementorresolutionin75%.Basedonthesereviews,bariatricsurgeryhasasignificanteffectonhypertension,inducingresolutionorimprovementinthemajorityofcases.
Sleep apnea
Thereislimitedhigh-levelevidenceregardingtheimpactofbariatricsurgeryonsleepapnea.Weidentifiedthreerandomizedclinicaltrials assessing the impact of adjustable gastric banding versusclinicalmanagementonsleepapnea.46–48ForAguiaretal.47, bar-iatric surgerywas effective in reducing neck andwaist circum-ference,inincreasingmaximumventilatorypressures,enhancingsleeparchitectureandreducingrespiratorysleepdisorders,specif-icallyobstructivesleepapnea.Ontheotherhand,Feigel-Guilleretal.48didnotfindsignificantdifferenceintherateofweaningfrom non-invasive ventilation between laparoscopic adjustablegastricbandingandmedicaltreatmentatoneyear(35%vs13%)orthreeyears(14versus21%).DecreasesintheApnea-HypopneaIndexwereobservedinthelaparoscopicadjustablegastricband-inggroupfrombaseline toyearone (44%,p=0.001)and frombaselinetoyearthree(-26%,p=0.04).
TheAmericanThoracicSocietyrecentlyreleasedaclinicalpracticeguidelineonthemanagementofsleepapnea.49TheirconditionalrecommendationforpatientswithsleepapneaandaBMIof35kg/m2,whoseweighthasnot improveddespiteparticipating ina comprehensiveweight-loss lifestyle intervention program andwhohaveno contraindications, is to referpatients forbariatricsurgery evaluation. They, however, assessed certainty in the es-timatedeffectasvery low.Morerandomizedcontrol trials,par-ticularlyincludingothertypesofsurgeriesthanadjustablegastricbanding,arethusneededtoconfirmthesefindingsgiventhehighdegreeofheterogeneityusingrespiratoryeventsscoring.
Lipid metabolism
Improvementsinlipidmetabolismhavebeenreportedconsistentlyin various prospective and retrospective studies. Contemporarybariatric surgical techniques produce significant improvementsinserumlipids,butchangesvarywidely, likelyduetoanatomicalterationsuniquetoeachprocedure.AliteraturereviewbyHef-fronetal.7 identified178studies,with25,189subjects, report-ingchanges in lipidsfrombaselinetooneyearaftersurgery. In
Canadian Adult Obesity Clinical Practice Guidelines 7
patientsundergoinganybariatricsurgerycomparedtobaseline,therewere significant reductions in total cholesterol (TC, -28.5mg/dL), lowdensity lipoproteincholesterol(LDL-C,-22.0mg/dL)andtriglycerides(-61.6mg/dL),andasignificantincreaseinhighdensitylipoproteincholesterol(6.9mg/dL)atoneyear(p<0.00001for all). Themagnitudeof this changewas significantly greaterthanthatseeninnon-surgicalcontrolpatients(e.g.LDL-C;-22.0mg/dLvs.-4.3mg/dL).Whenassessedseparately,themagnitudeofchangesvariedgreatlybysurgicaltype(pinteraction<0.00001;e.g.LDL-C:DS-42.5mg/dL,Roux-en-Ygastricbypass-24.7mg/dL, adjustable gastric banding -8.8 mg/dL, sleeve gastrectomy-7.9mg/dL). In thecasesofadjustablegastricbanding (TCandLDL-C)andsleevegastrectomy(LDL-C),theresponseatoneyearfollowingsurgerywasnotsignificantlydifferentfromnon-surgicalcontrolpatients.Thesedifferencesmayberelevantindecidingthemostappropriatetechniqueforagivenpatient.
Urinary incontinence
Urinary incontinence is extremely frequent in patients seekingbariatricsurgery.Inaseriesof470patientsundergoingbariatricsurgery,theprevalenceofurinaryincontinencewas66%.50Otherpelvicfloordisordersarealsofrequentand,ingeneral,surgicallyinducedweight-lossisveryefficientinimprovingtheseconditions.Lianetal.51performedameta-analysisoftheeffectsofbariatricsurgeryonpelvicfloordisorders.Elevencohortstudieswereidentified,involving784participantsassessedforpelvicfloordisorderswithavarietyofquestionnaires,beforeandafterbariatricsurgery.Bar-iatric surgerywas associatedwith a significant improvement inpelvicfloordisordersonthewhole,andwithsignificantimprove-ments in urinary incontinence andpelvic organprolapse. Therewasnosignificantimprovementinfecalincontinenceandsexualfunction.Inaprospectiveanalysisof140patientsundergoingbar-iatricsurgery,Saidandcolleagues52reportedthatsurgery-inducedweightlosswasassociatedwithanimprovementinstressurinaryincontinence (40%atbaselineversus15.5%atoneyear),urgeincontinence(37%atbaselinevs.8%),dysuria(20%atbaselinevs.3.4%)andQOLrelatedtourinarysymptoms(allP<.0001).Inaddition,reductioninprevalenceofurinaryincontinencewassig-nificantlyassociatedwithdecreasesinBMI(p=.01).53
Steatosis and steato-hepatitis
The non-alcoholic fatty liver disease (NAFLD) spectrum rangesfromhepatic steatosis tomore severenon-alcoholic steato-hep-atitis(NASH)andfibrosisthatcanprogresstocirrhosis,end-stageliverdisease,andhepatocellularcarcinoma.TheprevalenceofNA-FLDisestimatedtobearound70%inpeoplelivingwithobesityand85%to95%inpatientswithsevereobesity.Theprevalenceofnonalcoholicsteatohepatitisisashighas18.5%inpeoplelivingwithobesityand33%inthoselivingwithsevereobesity.Atpres-ent, interventionsforNAFLDfocusonweight lossandimprove-ment in insulinresistanceandassociatedcomorbidities.Medicaltreatmentforweightlosswithdrugs,nutrition,exerciseandotherpsychological/behaviouralinterventionshaslimitedefficacy,espe-ciallyinthoselivingwithsevereobesity.Ontheotherhand,liversteatosis,steatohepatitisandevenliverfibrosisappeartoimprove
orcompletelyresolveinthemajorityofpatientsafterbariatricsur-gery-inducedweightloss.54Inasystematicreviewoftheliterature(15 studieswith 766 paired liver biopsies),9 the pooled propor-tionofpatientswithimprovementorresolutioninsteatosiswas91.6%(95%CI,82.4%–97.6%),81.3%insteatohepatitis(95%CI,61.9%–94.9%),65.5%infibrosis(95%CI,38.2%–88.1%),and69.5%forcompleteresolutionofnonalcoholicsteatohepa-titis (95%CI,42.4%–90.8%).Lassaillyetal.55prospectively fol-lowed109patientswithbiopsy-provennonalcoholic steatohep-atitis who underwent bariatric surgery. One year after surgery,nonalcoholic steatohepatitis had disappeared from 85%of thepatients (95%CI, 75.8%–92.2%). Nonalcoholic steatohepatitisdisappearedfromahigherproportionofpatientswithmildnon-alcoholicsteatohepatitisbeforesurgery(94%)thanseverenonal-coholicsteatohepatitis(70%)(p<.05),accordingtoBruntscore.
Renal function
Obesityisanindependentriskfactorforthedevelopmentandpro-gressionofchronickidneydisease.However,dataonthebenefitsofbariatricsurgeryinpatientslivingwithobesitywhohaveimpairedkidney function are limited.A recent systematic review andme-ta-analysis56assessedtheimpactofbariatricsurgeryonglomerularfiltrationrate,proteinuriaoralbuminuria.Theauthorsincluded30observational studies and founda significant reduction inhyper-filtration,albuminuriaandproteinuriaafterbariatricsurgery.Mainlimitationswerethelackofrandomizedcontroltrialsandlong-termfollow-up. In another systematic review of the impact of bariat-ricsurgeryonrenal function inpatientswithT2DM,Zhouetal57 identified29studies(fourrandomizedcontrolledtrials,fivecohortstudies,20beforeand-afterstudies;allatmoderatetohighriskofbias)involving18,172patients.Analysesofchangesbeforeandaf-tersurgeriessuggestedasignificantlylowerproportionofalbumin-uria(difference-21.2%,95%CI-28.8%to-13.5%),24-hoururinealbumin excretion rate (weightedmeandifference -48.78mg/24heartrate,95%CI-75.32to-22.24)andurinealbumin-to-creat-inineratio (uACR) (weightedmeandifference-16.10mg/g,95%CI –-22.26 to –-9.94) after surgery. Compared with nonsurgicaltreatment,bariatricsurgerywasassociatedwithastatisticallylow-erlevelofuACRandlowerriskofnewonsetalbuminuria(OR.18,95% CI.03-.99 from randomized controlled trials). Even thoughlow-quality evidence suggests that bariatric surgery possibly im-proves albuminuria and uACR in patientswith T2DM, its effectsonotheroutcomesareuncertain. Large, randomizedprospectivestudieswithalongerfollow-upareneeded.
Does bariatric surgery decrease long-term mortality risk?
IntheSOSstudy,1surgicaltreatmentswereshowntodecreasetheincidenceof total and fatal cardiovascular eventsover20yearscomparedtocontemporaneouslymatchedcontrolsofthoselivingwithobesityreceivingusualcare.Therewere129deaths inthecontrolgroupand101deathsinthesurgerygroup.Thehazardratioadjustedforage,sexandriskfactorswas0.71inthesurgerygroup (p=0.01) as comparedwith the control group. Themostcommoncausesofdeathweremyocardialinfarctionandcancer.Analyses of the SOS data failed to demonstrate an associationbetween initialBMIandpostoperativehealthbenefits.Eventhemagnitudeofsurgery-inducedweightlossdidnotpredictcardio-vasculareventsinthatcohort,indirectlypointingtowardweightloss-independentbeneficialmechanisms.
Inameta-analysisofthepublishedliteratureonlong-term(>2years)mortality after bariatric surgery, Cardoso et al.2 identified 12 ob-servationalstudies involving27,258operatedpatientsand97,154non-operatedcontrolsofthoselivingwithobesity.Eightstudieswereeligibleforthemeta-analysis,whichshowedareductionof41%inall-causemortality(hazardratio,0.59;95%CI0.52-0.67;p<.001).
Indeed, surgical weight loss seems to reduce the incidence ofsomecancerformsandcancer-relatedmortality.IntheSOStrial,59 thenumberoffirst-timecancersafterinclusionwaslowerinthesurgerygroup (n=117) than in thecontrolgroup (n=169;heartrate 0.67, 95%CI 0.53-0.85, p=0.0009). Bariatric surgerywasassociatedwithreducedcancerincidenceinwomenwithobesitybutnotinmenlivingwithobesity.
Is bariatric surgery indicated in patients with Class I obesity (BMI 30–35)?
With the improved understanding of hormonal and metabol-icchanges relatedto the intestinalbypass,bariatric surgeryhasevolvedconceptuallyfrombariatricsurgerytometabolicsurgery,particularlyforpatientswithametaboliccomplication(especiallyT2DM),thatismoreofaproblemthanweightitself.AnumberofrandomizedtrialshavelookedattheimpactofsuchsurgeriesonT2DM, compared to thebestmedicalmanagement.5,60–62 Thesestudies were summarized in a meta-analysis by Cohen et al.10 lookingatpatientswithBMIof30–40kg/m2undergoingRoux-en-Ygastricbypassvs.medical treatment.10A totaloffive ran-domizedcontroltrialswereidentified,with43.3%ofthepatientswithaBMIbelow35kg/m2.Roux-en-Ygastricbypasssignificantlyimprovedtotalandpartial remissionofT2DM(OR17.48; (95%CI4.28-71.35)andOR20.71(95%CI5.16–83.12),respectively).HbA1cwasalsoreducedatlongestfollow-upinthesurgerygroup(−1.83[95%CI−2.14;−1.51]).Thismeta-analysisreinforcedtheviewthataddingmetabolicsurgery,particularlyRoux-en-Ygastricbypass,tothebestmedicaltreatmentisagoodoptionfortheman-agementofuncontrolledT2DMinpatientswithaBMI30kg/m2.
TheplaceofmetabolicsurgeryinthemanagementofT2DMwasrec-ognizedbytheInternationalFederationonDiabetesin2011.42Thispo-sitionstatementcalledforbariatricsurgerytobeconsideredearlierineligiblepatients,tohelpstemtheseriouscomplicationsthatcanresultfromdiabetes.InadditiontoconsideringsurgeryinpeoplewithT2DMandaBMI≥35kg/m2,theInternationalFederationonDiabetestaskforcestatedthatsurgeryshouldbeconsideredasanalternativetreat-mentoptioninpatientswithaBMIbetween30and35kg/m2whendi-abetescannotbeadequatelycontrolledbyoptimalmedicalregimens,especially in thepresenceofothermajorcardiovasculardisease riskfactors.In2016,over50internationalmedicalsocietiesendorsednewguidelineswheremetabolicsurgerywasincludedinthetreatmental-gorithmforpatientswithuncontrolledT2DMandBMIabove30kg/m2.63Othermetabolicoutcomeswerealsoimprovedinpatientswithmildtomoderateobesity.Ikramuddinetalrandomized120patientswithBMIbetween30and40kg/m2toRoux-en-Ygastricbypassver-susintensivemanagementandlookedatacompositemainendpointofhyperglycemia,hypertensionanddyslipidemiaresolution.11At12months,theprimaryendpointwasreachedin49%(95%CI,36%–63%)versus19%(95%CI10%–32%)ofthesurgicalversusmedicalpatients,respectively(OR,4.8;95%CI,1.9–11.7).Participantsinthegastricbypassgrouprequired3.0fewermedications(mean,1.7vs4.8;95%CIforthedifference,2.3-3.6)andlost26.1%vs.7.9%oftheirinitialbodyweightcomparedwiththelifestyle-medicalmanagementgroup(difference,17.5%;95%CI,14.2%–20.7%).Regressionanal-ysesindicatedthatachievingthecompositeendpointwasprimarilyattributabletoweightloss.
ThissimplifiedduodenalswitchtechniquehasbeenputforwardbySánchez-Pernaute.64 Much like the duodenal switch developed byMarceau65,66 andfirstperformed laparoscopicallybyGagner,65 it in-volvesthecreationofasleevegastrectomy,buttheduodenumistran-sectedandconnectedtoanomega-shapedloopofsmallbowel(Fig-ure1)Thisnewprocedurehastheadvantageofbeingsimplerthantheduodenalswitchbecauseonlyone intestinalanastomosis isneededinsteadoftwo.Theotherpotentialbenefitsaretodecreasetherateofperioperativecomplicationsandincreaseaccesstothistypeofsurgery.Inaddition,thelengthofthecommonintestinalchannelallowingdi-gestionandabsorption(250cm)ismorethandoubledcomparedtostandardduodenalswitch (100cm),whichcouldattenuateside-ef-fects related to dietary fat- and fat-soluble vitamin malabsorption.ThisprocedurewasrecentlyendorsedbytheInternationalFederationfor theSurgeryofObesityandAmericanSocietyforMetabolicandBariatricSurgery,67basedon its similaritiesandcommonlyaccepteddecreasedriskcomparedtostandardduodenalswitch.Single-anasto-mosisduodeno-ileostomyisemergingasapotentialoptionforsleeve
Canadian Adult Obesity Clinical Practice Guidelines 9
gastrectomyweightregainorT2DMrecurrences.Asinglesmallseriesof16patientswhohadtwo-stagesingle-anastomosisduodeno-ileos-tomyexperiencedan increase inexcessweight loss from39.5%to72%twoyearsafterthesecondstage(n=5).RemissionrateforT2DMwas88%,60%forhypertension,and40%fordyslipidemia.
Gastric plication
LaparoscopicgastricplicationwasfirstdescribedbyTalebpouretal.68 Thisprocedureconsists in imbricating thegreater curvatureof thestomachwithtwolayersofnon-absorbablesutures.Theoverallgoalistoduplicatetheeffectsofasleevegastrectomy,whileavoidinganygastricstaplingor resection.Theprocedure is,however,associatedwithsignificantpostoperativenauseaandfoodintoleranceanddoesnotseemtoreducetheriskofgastricleak.Asystematicreviewidenti-fied14studiesinvolving1450patientswhounderwentgastricplica-tion.69Excessweightlossrangedfrom32%to74%withfollow-upfromsixto24months.Nomortalitywasreportedinthesestudiesandtherateofmajorcomplicationsrequiringreoperationrangedfromnilto15.4%(average3.7%).However,itremainsunclearifweightlossfollowing laparoscopicgastricplication isdurable inthe long-term.Two-yearoutcomeswereassessedinarandomizedcontroltrialcom-paringsleevegastrectomytogastricplication.Attwoyears,thetotalweight loss and complication rateswerenot significantly differentbetweenthetwogroups.68Additionalcomparativetrialsandlong-termfollow-upareneededtofurtherdefinetheroleoflaparoscopicgastricplicationinthesurgicalmanagementofobesity.
Single-anastomosis gastric bypass
Roux-en-Ygastricbypasshas longbeen consideredas thegoldstandard in bariatric surgery, offering a good compromise be-tweenbenefits(weightloss,QOL,remissionofcomorbidities)andsurgical risksandsideeffects. Itwas recently replacedbysleevegastrectomyasthemostcommonbariatricprocedure.However,sometechnicallimitations(difficultyincreatingagastrojejunosto-my)andtheriskofweightandcomorbiditiesrecidivismhaveledtothedevelopmentofsingle-anastomosisgastricbypass(SAGB).Thisprocedurewas initiallydescribed in2001byRutledge, andconsistsofcreatingalongandnarrowgastricreservoir(+/-10cm,vs.5cm longforstandardRoux-en-Ygastricbypass)associatedwithasingle-looptypicallylonger(biliopancreaticlimbof200cm).ThistechniqueisincreasinglypopularinEuropeandAsiaandhasbeenendorsedbytheInternationalFederationfortheSurgeryofObesity.70 It is,however,notcurrentlyapprovedoutsideof Insti-tutional Review Board protocols in the U.S. Long-term benefitsofSAGBcomparedtostandardRoux-en-Ygastricbypassarestillquestionedregardingtheriskofbilerefluxandlong-termriskofesophagealandgastriccancerassociatedwithchronicexposureto bile acids. A recent randomized control trial compared sin-gle-anastomosis gastric bypass to Roux-en-Ygastric bypass andsleeve gastrectomy (200 patients in each groups). The authorsreportedsuperiorweightloss(98%vs.76%vs.77%inthesin-gle-anastomosisgastricbypass,sleevegastrectomyandRoux-en-Ygastricbypassgroups, respectively)andsimilar remission rateofmetabolicsyndrome,includingremissionofT2DMin94%versus87%versus90%afterSAGB,sleevegastrectomyandRoux-en-Y
Itisconservativelyestimatedthatapproximately600,000to1,200,000CanadiansmightbeeligibleforbariatricsurgeryassumingthattwotofourpercentoftheCanadianadultpopulationislivingwithsevereobesity.72OnlyafractionofCanadiansseeksurgicalinterventionforobesity. Approximately 10,000 bariatric surgeries were performedin2017.Manypatientsareinterestedinlessinvasiveproceduresinorder to decrease postoperative complication rates, hospitalizationandrisksofmicronutrientdeficienciestypicallyassociatedwithstan-dard surgical therapies.Anumberofendoscopicapproacheshaveemergedovertimeandaretypicallyplacedbetweenmedicaltherapyandsurgicaltherapy,intermsofeffectiveness,risks,andside-effects.
Intra-gastric balloons
Intra-gastricballoonswerefirstdescribedin1982byNiebenetal.73 and represent theoldest endoscopic procedure forweight loss.Multiplemodificationshavebeenrealizedtoimprovethetolera-bility,riskofperforationandeaseofplacementandretrieval.Mostballoonsstillrequireuppergastrointestinalendoscopywithseda-tionorgeneralanesthesia,andneedtoberetrievedafterthreetosixmonthsusing the same technique.Mostpatientsexperiencesomesideeffects,likenausea(24%),vomiting(2.7%),abdominalfullness (6.3%) or pain (14%), deflation (6%) and gastric ulcer(12.5%).74Rarecomplicationscanalsooccur,includinggastricoresophagealperforation, smallbowelobstructionandhypoxiaatthetimeofextraction.Inameta-analysisof20randomizedcontroltrialsinvolving1195patients,Saberetal.calculatedthefollowingsignificanteffect sizes:1.6and1.3kg/m2 foroveralland three-monthsBMI loss, and4.6 kg and4.8 kg for overall and three-monthweight loss.74 In anothermeta-analysis by Zhenget al.75
sistsofplacementofagastrostomytubeandanexternaldevicetofacilitatedrainageofabout30%ofthecaloriesconsumedinameal,inconjunctionwithlifestylemodifications.Thompsonetal.84 randomized 207 patients in a 2:1 ratio to treatmentwithAspireAssist® plus lifestyle counselling (n=137; mean BMI was42.2+/-5.1kg/m2)orlifestylecounsellingalone(n=70;meanBMIwas40.9+/-3.9kg/m2).At52weeks,participants intheAspi-reAssist® grouphad lost amean (+/-s.d.) of 12.1+/- 9.6% to-talbodyweight,whereasthoseinthelifestylecounsellinggrouphad lostameanof3.5+/-6.0%totalbodyweight, (p<0.001).Most adverse events were those known to be associatedwithpercutaneousendoscopicgastrostomytubes (abdominalpain in38%,nausea/vomiting in17%,peristomalbacterial infection in13.5%).Seriousadverseeventswerereportedin3.6%ofpartic-ipants,includingsevereabdominalpain,peritonitis,gastriculcerand tube replacement.Medium-term results are starting to ap-pear,withstudiesconfirmingmaintenanceofweightloss,at19+/-13%weightloss,uptofouryears.85Eventhoughtheseresultsseem to be promising, patients and physicians’ acceptability oftheprocedure,theneedforlong-termnutritionalsurveillanceandlackoflong-termdataandcostitselfareamongfactorslimitingtheadoptionofthisprocedure.
7. Heffron SP, ParikhA, VolodarskiyA, et al. Changes in lipid profile of obesepatientsfollowingcontemporarybariatricsurgery:Ameta-analysis.AmJMed.2016;129(9):952-959.doi:10.1016/j.amjmed.2016.02.004
8. Wilhelm SM, Young J, Kale-Pradhan PB. Effect of bariatric surgery on hy-pertension: A meta-analysis. Ann Pharmacother. 2014;48(6):674-682.doi:10.1177/1060028014529260
11. IkramuddinS,Korner J, LeeWJ, et al. Roux-en-Ygastricbypass vs intensivemedicalmanagement for the control of type 2 diabetes, hypertension, andhyperlipidemia: The Diabetes Surgery Study randomized clinical trial. JAMA.2013;309(21):2240-2249.doi:10.1001/jama.2013.5835
12. NguyenNT,KimE,VuS,PhelanM.Ten-yearoutcomesofaprospectiverandom-ized trial of laparoscopic gastric bypass versus laparoscopic gastric banding.AnnSurg.2018;268(1):106–113.doi:10.1097/SLA.0000000000002348
13. Robert M, Espalieu P, Pelascini E, et al. Efficacy and safety of one anasto-mosis gastric bypass versus Roux-en-Y gastric bypass for obesity (YOME-GA): A multicentre, randomised, open-label, non-inferiority trial. Lancet.2019;393(10178):1299-1309.doi:10.1016/S0140-6736(19)30475-1
14. UnickJL,BeaversD,BondDS,etal.Thelong-termeffectivenessofalifestyleintervention in severely obese individuals. Am JMed. 2013;126(3):236-242.doi:10.1016/j.amjmed.2012.10.010
21. AngrisaniL,SantonicolaA,IovinoP,etal.IFSOworldwidesurvey2016:Primary,endoluminal, and revisionalprocedures.ObesSurg.2018;28(12):3783-3794.doi:10.1007/s11695-018-3450-2
24. Ashrafian H, le Roux CW.Metabolic surgery and gut hormones - A reviewof bariatric entero-humoral modulation. Physiol Behav. 2009;97(5):620-631.doi:10.1016/j.physbeh.2009.03.012
25. Marceau P, Biron S, Marceau S, et al. Long-termmetabolic outcomes 5 to20 years after biliopancreatic diversion. Obes Surg. 2015;25(9):1584-1593.doi:10.1007/s11695-015-1599-5
35. SjöholmK, Sjöström E, Carlsson LMS, PeltonenM.Weight change-adjustedeffectsofgastricbypasssurgeryonglucosemetabolism:2-and10-yearresultsfromtheSwedishObeseSubjects(SOS)study.DiabetesCare.2016;39(4):625-631.doi:10.2337/dc15-1407
36. Ding SA, Simonson DC, Wewalka M, et al. Management in patients withtype 2 diabetes: A randomized clinical trial. J Clin Endocrinol Metab.2015;100(7):2546-2556.doi:10.1210/jc.2015-1443
40. Hedberg J, SundbomM. Superiorweight loss and lowerHbA1c 3 years af-ter duodenal switch compared with Roux-en-Y gastric bypass - A random-ized controlled trial. SurgObes RelatDis. 2012;8(3):338-343. doi:10.1016/j.soard.2012.01.014
41. PanunziS,CarlssonL,DeGaetanoA,etal.Determinantsofdiabetesremissionand glycemic control after bariatric surgery. Diabetes Care. 2016;39(1):166-174.doi:10.2337/dc15-0575
44. RicciC,GaetaM,RausaE,MacchitellaY,BonavinaL.Early impactofbariat-ric surgery on type II diabetes, hypertension, and hyperlipidemia: A system-aticreview,meta-analysisandmeta-regressionon6,587patients.ObesSurg.2014;24(4):522-528.doi:10.1007/s11695-013-1121-x
52. AitSaidK,LerouxY,MenahemB,DoerflerA,AlvesA,TillouX.Effectofbar-iatric surgery on urinary and fecal incontinence: Prospective analysis with1-year follow-up. Surg Obes Relat Dis. 2017;13(2):305-312. doi:10.1016/j.soard.2016.08.019
53. BurgioKL,RichterHE,ClementsRH,ReddenDT,GoodePS.Changes inuri-nary and fecal incontinence symptomswithweight loss surgery inmorbidlyobese women. Obstet Gynecol. 2007;110(5):1034-1040. doi:10.1097/01.AOG.0000285483.22898.9c
54. Cazzo E, Pareja JC, Chaim EA. Nonalcoholic fatty liver disease and bariatricsurgery: A comprehensive review. Sao Paulo Med J. 2017;135(3):277-295.doi:10.1590/1516-3180.2016.0306311216
55. Lassailly G, Caiazzo R, Buob D, et al. Bariatric surgery reduces features ofnonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology.2015;149(2):379-388.doi:10.1053/j.gastro.2015.04.014
58. Christou N V., Sampalis JS, LibermanM, et al. Surgery decreases long-termmortality,morbidity,andhealthcareuseinmorbidlyobesepatients.AnnSurg.2004;240(3):416-424.doi:10.1097/01.sla.0000137343.63376.19
61. Courcoulas AP, Belle SH, Neiberg RH, et al. Three year outcomes of bariat-ric surgeryvs. lifestyle intervention for type2diabetesmellitus treatment:Arandomized trial. JAMA Surg. 2015;150(10):931–940. doi:10.1001/jama-surg.2015.1534
62. IkramuddinS,KornerJ,LeeWJ,etal.Lifestyleinterventionandmedicalman-agementwithvswithoutRoux-en-YgastricbypassandcontrolofhemoglobinA1c, LDL cholesterol, and systolic blood pressure at 5 years in theDiabetesSurgeryStudy.JAMA.2018;319(3):266-278.doi:10.1001/jama.2017.20813
Canadian Adult Obesity Clinical Practice Guidelines 13
66. Marceau P, Biron S, Bourque RA, PotvinM, Hould FS, Simard S. Biliopancre-atic diversion with a new type of gastrectomy. Obes Surg. 1993;3(1):29-35.doi:10.1381/096089293765559728
67. BrownWA, Ooi G, Higa K, Himpens J, Torres A. Single anastomosis duode-nal-ileal bypass with sleeve gastrectomy/one anastomosis duodenal switch(SADI-S/OADS) IFSO position statement. Obes Surg. 2018;28(5):1207-1216.doi:10.1007/s11695-018-3201-4
68. TalebpourM,SadidD,TalebpourA,SharifiA,DavariFV.Comparisonofshort-term effectiveness and postoperative complications: Laparoscopic gastric pli-cation vs laparoscopic sleeve gastrectomy. Obes Surg. 2018;28(4):996-1001.doi:10.1007/s11695-017-2951-8
69. JiY,WangY,ZhuJ,ShenD.Asystematicreviewofgastricplicationforthetreat-ment of obesity. Surg Obes Relat Dis. 2014;10(6):1226-1232. doi:10.1016/j.soard.2013.12.003
76. De Peppo F, Caccamo R, Adorisio O, et al. The Obalon swallowable intra-gastric balloon in pediatric and adolescentmorbid obesity. Endosc Int Open.2017;5(1):E59-E63.doi:10.1055/s-0042-120413
78. VixM,DianaM,Marx L, et al.Managementof staple line leaks after sleevegastrectomyinaconsecutiveseriesof378patients.SurgLaparoscEndoscPercu-taneousTech.2015;25(1):89-93.doi:10.1097/SLE.0000000000000026
79. RohdeU,HedbäckN,Gluud LL,Vilsbøll T,Knop FK. Effectof the EndoBarri-erGastrointestinal Liner onobesity and type2diabetes:A systematic reviewandmeta-analysis. Diabetes, ObesMetab. 2016;18(3):300-305. doi:10.1111/dom.12603
80. BetzelB,HomanJ,AartsE,etal.Acutepancreatitisasanadverseeventinpa-tients with the duodenal-jejunal bypass liner. Endoscopy. 2015;47(11):1050-1053.doi:10.1055/s-0034-1392226
82. TarnoffM, Rodriguez L, Escalona A, et al. Open label, prospective, random-ized controlled trial of an endoscopic duodenal-jejunal bypass sleeve versuslowcaloriedietforpre-operativeweightlossinbariatricsurgery.SurgEndosc.2009;23(3):650-656.doi:10.1007/s00464-008-0125-4
84. ThompsonCC, AbuDayyeh BK, Kushner R, et al. Percutaneous gastrostomydevice for the treatmentof class II andclass III obesity:Resultsofa random-ized controlled trial. Am J Gastroenterol. 2017;112(3):447-457. doi:10.1038/ajg.2016.500